Spiramycin
ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: espiramicin, foromacidin, provamycin, rovamicina, rovamycin, rovamycine, selectomycin, sequamycin, spiramycins, stomamycin
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Spiramycin is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2018. Recorded indications include Prophylaxis of congenital toxoplasmosis.
- Indications: Prophylaxis of congenital toxoplasmosis.
- ATC code: J01FA02 (Macrolides).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Prophylaxis of congenital toxoplasmosis
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2018-07-02 | PMDA | — | Sanofi KK | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J01FA02 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS › Macrolides |
J01RA04 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › COMBINATIONS OF ANTIBACTERIALS › Combinations of antibacterials |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Cholestasis | 247.7 |
| Hepatocellular injury | 234.0 |
| Rash maculo-papular | 206.7 |
| Toxic epidermal necrolysis | 181.4 |
| Acute generalised exanthematous pustulosis | 113.9 |
| Drug reaction with eosinophilia and systemic symptoms | 110.1 |
| Eosinophilia | 110.0 |
| Hepatic cytolysis | 96.9 |
| Acute kidney injury | 78.0 |
| Cross sensitivity reaction | 71.3 |
| Hypertransaminasaemia | 66.9 |
| Respiratory distress | 63.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Spiramycin is on its molecule page.
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | 5289394 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Spiramycin used for?
DrugCentral lists the following indications for Spiramycin: Prophylaxis of congenital toxoplasmosis.
When was Spiramycin first approved?
Spiramycin was first approved by the PMDA in 2018.
Browse: all drugs starting with S · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4711 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL6195749 — compound record and bioactivity
- PubChem CID 5289394 — chemical identifiers
- DrugBank DB06145 — drug record
- FDA UNII 71ODY0V87H — substance identity
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.